This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will uniQure Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in uniQure.
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Gene Therapy the Next Best Thing: Here's Why (Revised)
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene Therapy the Next Best Thing: Here's Why
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
uniQure N.V. (QURE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in uniQure N.V. (QURE).
uniQure N.V. (QURE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in uniQure N.V. (QURE).
UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 30.12% and -53.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -10.67% and 61.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
by Zacks Equity Research
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Is the Options Market Predicting a Spike in uniQure (QURE) Stock?
by Zacks Equity Research
Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.
uniQure (QURE) Jumps: Stock Rises 8.9%
by Zacks Equity Research
uniQure (QURE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
by Indrajit Bandyopadhyay
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
Novartis Gets Approval for Gene Therapy Luxturna in Europe
by Zacks Equity Research
Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.
uniQure Up on Positive Data From Mid-Stage Hemophilia Study
by Zacks Equity Research
uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
Options Traders Expect Huge Moves in uniQure (QURE) Stock
by Zacks Equity Research
uniQure (QURE) needs investors to pay close attention to the stock based on moves in the options market lately.
UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 6.35% and -6.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?